UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
------------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
------------------------
Date of Report (Date of earliest event reported): January 28, 2004
IMPAX LABORATORIES, INC.
----------------------------------------------------------------
(Exact name of Registrant as specified in its charter)
Delaware 0-27354 65-0403311
------------------------------- ----------------- ----------------------
(State or other jurisdiction of (Commission (I.R.S. Employer
incorporation or organization) File Number) Identification Number)
30381 Huntwood Avenue
Hayward, CA 94544
------------------------------------------------------------
(Address of principal executive offices, including zip code)
Registrant's telephone number, including area code: (510) 476-2000
--------------
Item 9. Regulation FD Disclosure
On January 28, 2004, Impax Laboratories Inc. issued a press release
announcing that the U.S. Food and Drug Administration granted final approval to
the Company's Abbreviated New Drug Application for its generic version of
Wellbutrin(R) SR (Bupropion Hydrochloride) 100mg Controlled Release Tablets and
granted tentative approval for the Company's generic version of Wellbutrin(R) SR
150mg Controlled Release Tablets. A copy of the press release is attached as
Exhibit 99.1 and is incorporated herein by reference.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Impax Laboratories, Inc.
Date: January 28, 2004
By: /s/ Cornel C. Spiegler
----------------------------------
Cornel C. Spiegler
Chief Financial Officer